Samyang Holdings Biopharmaceuticals will develop into a global company with a mission to realize enriched and healthy human life through unceasing efforts and aggressive investments, firmly grounded on present achievements
Research at Samyang Holdings Biopharmaceuticals R&D center focuses on pharmaceuticals and medical devices. On the foundation of previously acquired platform technologies, the center is actively conducting R&D, thus unveiling a variety of products.
The signature products of Samyang Holdings Biopharmaceuticals include cytotoxic anticancer drugs (for lung cancer, ovarian cancer, blood cancer, etc) , pain management patches, smoking cessation adjuvant patches, anti-inflammatory patches, and biodegradable surgical sutures, all of which have been well received by patients and medical staff and highly acclaimed in the global market.
The scientists at Samyang Holdings Biopharmaceuticals are experts in their fields with years of research experience in new drug development and drug delivery systems from leading academic and industrial institutions.
The key researchers at Samyang Holdings Biopharmaceuticals have contributed an average of 3.13 papers to the SCI-level international journals, a figure far higher than the average of 0.17 by the researchers in other companies in Korea (Ministry of Education, Science, and Technology, Analysis of Science and Technology Theses,
November 2010). Furthermore, the Biomedical Research Center at Samyang Holdings Biopharmaceuticals currently possesses over 999 registered patents, 711 of which are international patents. Among these, 50 key patents are being used in manufacturing products, thus generating sales. Based on these diverse patents, Samyang Holdings Biopharmaceuticals continues to make unceasing efforts to utilize DDS and to develop enhanced new drugs.
31 Jongno 33-gil, jongno-gu, Seoul TEL +82-2-740-7116 FAX +82-2-743-6626
Copylight ⓒ 2013 Samyang Biopharmaceuticals Corporation. All rights Reserved.
